AbilityPharma closes €7 million round for metastatic pancreatic cancer drug ABTL0812
AbilityPharma closes €7 million round to fully fund its international Phase 2b clinical trial with the antitumor drug ABTL0812 in pancreatic cancer patients.
Source: asebio.com